SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened community engagement driven by anticipation surrounding ongoing monthly burn initiatives and the development of new ecosystem projects. Supporters are closely watching the chart for signs of a turnaround, frequently discussing the potential for a long-term recovery and increased utility within the blockchain.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with holders actively promoting its organic growth and whale accumulation trends. The community remains highly engaged by leveraging the project's playful 'dad joke' branding to maintain visibility and momentum across various social platforms.

Optical Cable Corp. engages in the business of manufacturing fiber optic and copper data communication cabling and connectivity solutions primarily for the enterprise market and various harsh environment, specialty markets, and the wireless carrier market offering integrated suites of high-quality products which operate as a system solution or seamlessly integrate with other components. Its products include fiber optic and copper cabling, hybrid cabling, fiber optic and copper connectors, specialty fiber optic, copper and hybrid connectors, fiber optic and copper patch cords, pre-terminated fiber optic and copper cable assemblies, racks, cabinets, datacom enclosures, patch panels, face plates, multimedia boxes, fiber optic reels, and other cable and connectivity management accessories. The company was founded on June 10, 1983 and is headquartered in Roanoke, VA.

Optical Cable Corp.

Optical Cable Corp is trending as investors monitor its role in the data center and fiber infrastructure boom, with the community closely tracking potential execution of its strategic partnership with Lightera. While sentiment remains divided between those betting on long-term value from increased fiber demand and those wary of the stock's low-float volatility and historical revenue headwinds, the ticker continues to attract attention during retail momentum cycles.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven low-cap memecoin on Solana, with investors actively discussing its rapid growth and the developer's commitment to community engagement through frequent airdrops and transparency. Supporters are rallying behind the project's 'dumb send' philosophy, frequently comparing its early-stage potential to other successful runners while focusing on social media trending and viral expansion.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is seeing renewed momentum as investors track the project's recent listing on Robinhood alongside major milestones in protocol revenue and ongoing supply-reduction efforts. The community is actively debating the project's long-term utility as the central liquidity hub on Base, with many focused on upcoming growth phases and institutional-grade adoption.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors is trending as investors weigh its role as a "picks-and-shovels" play in the automotive and industrial AI buildout against recent analyst downgrades citing inventory and demand concerns. The community is actively debating whether its recent price action signals a long-term value opportunity or a trap amid broader volatility in the semiconductor sector.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is generating significant buzz following strong Q1 financial results and the announcement of a multi-million dollar share buyback, which has sparked intense debate among traders regarding potential short squeeze opportunities. While some investors are bullish on the company's long-term leadership in autonomous driving and physical AI, others remain skeptical, pointing to heavy institutional short interest and concerns over its ownership structure.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is attracting significant attention as investors weigh the potential long-term impact of GLP-1 weight-loss drugs on the dialysis sector against the company's strong fundamentals and consistent share repurchases. Community discussion is currently focused on the stock's recent volatility, its defensive value proposition, and the potential for strategic partnerships or acquisitions involving innovative medical device technology to improve patient outcomes.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

Dogwifhat (WIF) is facing intense community division as investors oscillate between frustration over stagnant, sideways price action and bullish anticipation of a potential breakout. While traders continue to debate its long-term viability and lack of utility, the sentiment remains polarized between those holding for a recovery to previous highs and those venting about the lack of consistent momentum.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins (PENGU) is generating significant buzz as community members highlight its unique 'phygital' strategy, including retail toy partnerships and ongoing product ecosystem developments, as major catalysts for long-term potential. While some investors remain cautious about broader market volatility, active discussions focus on accumulation during price consolidation and high expectations for future utility-driven growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.read more...

Candel Therapeutics (NASDAQ:CADL) Sees Large Volume Increase - Time to Buy?

Candel Therapeutics (NASDAQ:CADL) Sees Unusually-High Trading Volume - Should You Buy...

<ul class="summary-bullets"><li>The firm stated that the stock is deeply undervalued, with a discounted cash flow estimate of around $30 per share.</li><li>Investors are awaiting extended phase 3 data for CAN-2409 in prostate cancer, as well as from the late-stage trial in non-small cell lung cancer.</li><li>Last month, Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer.</li></ul>Shares of Candel Therapeutics (CADL) drew strong retail interest on Monday after a bullish brokerage call labeled the stock “significantly undervalued,” with optimism building ahead of key trial data in lung and prostate cancer.Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly. The brokerage expressed strong confidence in the stock’s outlook, stating that the shares are “deeply undervalued”, pointing to a discounted cash flow (DCF) estimate of around $30 per share and peak sales potential of $2.4 billion in prostate cancer.This represents a potential 370% upside from the stock’s Friday closing price of $6.37, when the stock recorded its highest intraday gains in more than 16 months. <a href="https://stocktwits.com/symbol/CADL">CADL shares</a> traded 0.5% lower in Monday’s pre-market.Cantor said the bullish view is backed by positive Phase 3 data, clear regulatory progress under a Special Protocol Agreement, limited competition, and a manageable safety profile. Additional upside could come from the company’s lung cancer program, which is advancing into late-stage trials.<h2 class="st-heading-2">CAN-2409 Shows Promise</h2>Last month, Candel Therapeutics reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer. After an additional year of follow-up, 50% of patients were still alive at two years, despite a poor response to prior treatments, the firm said.The therapy also showed improved survival compared with standard care and remained well-tolerated. Researchers found it helped activate the immune system and turn previously unresponsive tumors into ones that could respond to treatment.Extended phase 3 results for CAN-2409 in prostate cancer are <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">expected</a> at the American Urological Association 2026 meeting in May. Investors in Candel Therapeutics are waiting for updates on its late-stage trial in non-small cell lung cancer and on other programs such as CAN-3110.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier. Message volume on the platform surged by around 70% over a 24-hour period, according to Stocktwits data.One user said the current share price offers a “tremendous opportunity.”<stembedurl>https://stocktwits.com/drizz/message/650754597</stembedurl>Year-to-date, the stock has gained around 7%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-price-dropping-another-3-000-could-wipe-out-all-ceasefire-gains/cZBdJ8WRIyt">BTC Price Dropping Another $3,000 Could Wipe Out All Ceasefire Gains, Analyst Warns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CADL Stock Gets A Bullish Call Just Weeks Before Crucial Prostate Cancer Data Reveal

Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly.

CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside?

Equity

<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned a consensus recommendation of "Hold" from the eight analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and...

Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the company, MarketBeat...

FY2030 Earnings Forecast for CADL Issued By HC Wainwright

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Candel Therapeutics in a research note issued to...

Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7%

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling...

Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL

Portolan Capital Management LLC trimmed its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 14.7% during the third quarter, according to the company in its most recent Form 13F...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Current Price	$6.50
Prev Close	$7.04
Open	$7.04
Dividend Yield	0.00%
50-Day Moving Average	$5.29
Beta	1.39
Avg. Volume	1.28M
PE Ratio	-9.27

52-Week High	$7.66
52-Week Low	$4.34
Market Capitalization	$476.11M
EPS (Annual)	-$0.721
Price to Book	6.89
Revenue Per Employee	$0.00

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADLCandel Therapeutics Inc